Can Osimertinib be launched in 2023?

In November 2015, Osimertinib tablets received accelerated approval in the United States for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (as detected by an FDA-approved test) who have progressed during or after treatment with an EGFR TKI. Osimertinib has also received accelerated assessment status for this indication in the EU and is in Phase III development in several countries for first- and second-line and adjuvant treatment of advanced EGFR mutation-positive non-small cell lung cancer.

Patients whose cancer cells have EGFR mutations have poor prognosis and limited treatment options; therefore, there is a high unmet medical need. Studies have shown that osimertinib can effectively shrink tumors and slow the progression of the cancer in patients with these mutations. The drug also effectively prevents cancer from returning in patients with EGFR mutations who have undergone surgery to completely remove the cancer. Regarding safety, the adverse reactions of osimertinib are similar to those of other similar drugs and are considered acceptable.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.